Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 13/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648835 | 0.97 | UTS2R (0.55) | UTS2RDRD4ENPP2MCHR1PRKAA2 | |
| SCHEMBL4408251 | 0.92 | UTS2R (0.61) | UTS2RTEAD1DRD4MCHR1 | |
| SCHEMBL10126785 | 0.91 | UTS2R (0.52) | UTS2RPRKAA2 | |
| SCHEMBL4403534 | 0.90 | UTS2R (0.54) | UTS2RDRD4PRKAA2 | |
| SCHEMBL647404 | 0.89 | UTS2R (0.56) | UTS2RTEAD1DRD4MCHR1 | |
| SCHEMBL648921 | 0.88 | CHRM4 (0.50) | UTS2RPRKAA2 | |
| SCHEMBL4403508 | 0.85 | UTS2R (0.54) | UTS2RDRD4PRKAA2 | |
| SCHEMBL647341 | 0.84 | UTS2R (0.52) | UTS2RTEAD1DRD4MCHR1 | |
| SCHEMBL15480696 | 0.78 | UTS2R (0.55) | UTS2RDRD4MCHR1 | |
| SCHEMBL12199847 | 0.77 | MAOB (0.47) | UTS2RDRD4MCHR1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174964-B2 | AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2231600-B1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8569340-B2 | AMPK-activating piperidinyloxypyiridine carboxamide and sulfonamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8119809-B2 | AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | UTS2R 1535/4885TEAD1 2575/4885DRD4 4704/4885 |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | UTS2R 1535/4885TEAD1 2575/4885DRD4 4704/4885 |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | UTS2R 514/4885TEAD1 3214/4885DRD4 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.